Trial of personalised care after treatment-Prostate cancer: A randomised feasibility trial of a nurse-led psycho-educational intervention.
Aged
Aged, 80 and over
Cancer Survivors
/ psychology
Cost-Benefit Analysis
Delivery of Health Care
/ economics
Feasibility Studies
Humans
Male
Middle Aged
Patient Education as Topic
/ economics
Patient Satisfaction
Precision Medicine
/ economics
Prostatic Neoplasms
/ economics
Psychotherapy
/ economics
Quality-Adjusted Life Years
Surveys and Questionnaires
Treatment Outcome
general practice
needs assessment
nurse practitioners
patient care
prostate cancer
urology
Journal
European journal of cancer care
ISSN: 1365-2354
Titre abrégé: Eur J Cancer Care (Engl)
Pays: England
ID NLM: 9301979
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
22
02
2018
accepted:
21
10
2018
pubmed:
28
11
2018
medline:
23
7
2019
entrez:
28
11
2018
Statut:
ppublish
Résumé
The present parallel randomised control trial evaluated the feasibility of a nurse-led psycho-educational intervention aimed at improving the self-management of prostate cancer survivors. We identified 305 eligible patients from a district general hospital, diagnosed 9-48 months previously, who completed radical treatment, or were monitored clinically (ineligible for treatment). Ninety-five patients were recruited by blinded selection and randomised to Intervention (N = 48) and Control (N = 47) groups. Participant allocation was revealed to patients and researchers after recruitment was completed. For 36 weeks, participants received augmented usual care (Control) or augmented usual care and additional nurse support (Intervention) provided in two community hospitals and a university clinic, or by telephone. Data from 91 participants (Intervention, N = 45; Control, N = 46) were analysed. All feasibility metrics met predefined targets: recruitment rate (31.15%; 95% CI: 25.95%-36.35%), attrition rate (9.47%; 95% CI: 3.58%-15.36%) and outcome measures completion rates (77%-92%). Forty-five patients received the intervention, with no adverse events. The Extended Prostate Cancer Index Composite can inform the minimum sample size for a future effectiveness trial. The net intervention cost was £317 per patient. The results supported the feasibility and acceptability of the intervention, suggesting that it should be evaluated in a fully powered trial to assess its effectiveness and cost-effectiveness.
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Pagination
e12966Subventions
Organisme : Macmillan Cancer Support
ID : 4237574
Informations de copyright
© 2018 John Wiley & Sons Ltd.